17,261 trials
HIV · AIDS · Aging
Primary: Change in Acute Effects of Cannabis on Mobility Gait Speed (m/s) — 2.89; 3.11; 2.87; 2.99 m/s — p=0.17
Vulvar Lichen Sclerosus
Primary: Mean Change in Weekly Mean Worst Itch Numeric Rating Score (WI-NRS) — -4.0; -3.5 units on a scale
Metastatic Prostate Cancer · Castration-resistant Prostate Cancer · Prostatic Neoplasm
Primary: PSA Response Rate — 10; 44 Participants — p=0.0025
HIV Infection
Primary: Evaluation of the Safety of MVA HIV-B at Week 2 in Arm 1 — 22 Participants
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining (NEI Scale) — -2.4; -1.3 score on a scale
Non-small Cell Lung Cancer
Primary: Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors RECIST 1.1 (Brand Name) or Death, Whichever Occurs…
Amyotrophic Lateral Sclerosis · ALS
Primary: Safety Assessment of IFB-088 50 mg/Day in Patients With Bulbar-onset ALS. Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 10…
Metastatic Colorectal Cancer
Primary: Participants With Recurrence Free Survival for Colorectal Cancer Participants With Resected Liver Metastases — 69; 47 percentage of participants
Sjögren's Syndrome · Sjogren's Syndrome
Primary: Change From Baseline to Week 12 in ESSDAI Score — -5.60; -5.29 score on a scale
Colorectal Cancer · Pancreatic Cancer
Primary: Number of Participants Experiencing Adverse Events (AEs) — 10; 8; 10; 11 Participants
Monkeypox
Primary: Time to Lesion Resolution — 7; 8 Days
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
Head and Neck Cancer
Primary: Adverse Events - Evaluate Safety of a 7-injection Regimen of PepCan. — 23; 0; 0; 1 adverse event
Hidradenitis Suppurativa (HS)
Primary: Percent Change in Wound Size — 57.2 percentage change in wound size
Low-Grade Gliomas · Malignant Neoplasms, Brain · Soft Tissue Neoplasms
Primary: Best Overall Response Rate (Strata 1 and 2) — 15; 12 Participants